Author Archives: admin


10 students, alumni win NSF Graduate Research Fellowships – University of Georgia

Two current University of Georgia undergraduate students are among the 10 campus recipients of 2023 National Science Foundation Graduate Research Fellowships.

The NSF Graduate Research Fellowship Program helps ensure the quality, vitality and diversity of the scientific and engineering workforce of the United States. The program recognizes and supports outstanding graduate students who are pursuing full-time research-based masters and doctoral degrees in science, technology, engineering and mathematics (STEM) or in STEM education. The GRFP provides three years of support at $37,000 annually over a five-year fellowship period for the graduate education of individuals who have demonstrated their potential for significant research achievements in STEM or STEM education.

Begun in 1952, this fellowship program is the oldest and most prestigious of its kind; 42 recipients have gone on to become Nobel laureates, and more than 450 have become members of the National Academy of Sciences.

Typically, there are over 12,000 applications for these fellowships annually. This year, there were 2,552 students offered fellowships in all areas of science.

The UGA undergraduate students and alumni winners are:

Andres is a phenomenal student scholar with exceptional promise, said Rachel Roberts-Galbraith, assistant professor in the Franklin College of Arts and Sciences department of cellular biology. In our group, he has made exciting contributions to our goal of understanding how small signaling molecules called neuropeptides promote tissue regeneration and stem cell function. As his mentor, it has been very rewarding to be part of his journey.

Magahey and McSweeney join seven other NSF GRF winners nationally in the category of Geosciences Climate and Large-Scale Atmospheric Dynamics. The undergraduate institutions of the other seven winners were Cornell, Harvard, Princeton and Yale Universities, UC-Berkeley, Rochester Institute of Technology and Worcester Polytechnic Institute. UGA was the only institution with two winners in this category.

Shay and Killian are two of the best students Ive taught in 22 years at UGA, and the best at UGA are as good as the best, anywhere, said John Knox, Josiah Meigs Distinguished Teaching Professor in the Franklin College department of geography. He is also the undergraduate coordinator for the Atmospheric Sciences Program, and a recipient of this fellowship as an undergraduate in 1988. This august company among the top Ivy League schools indicates just how high above the rim the undergraduates in our atmospheric sciences program and geography department are playing.

Magahey and McSweeney have each been involved in research through CURO. McSweeney was first author on a paper based on his undergraduate thesis work published in January in Geophysical Research Letters, a major atmospheric science journal.

Killian and Shay are both self-motivated, independent, and extremely capable researchers. Im thrilled that their achievements and ideas have been recognized with this fellowship award, said Gabriel Kooperman, assistant professor in the department of geography. Ive been so fortunate to have had the opportunity to work with them on research for the last few years and I know they will go on to great success in graduate school.

Five UGA graduate students are also 2023 Fellowship winners:

See the original post:
10 students, alumni win NSF Graduate Research Fellowships - University of Georgia

Creative Medical Technology Holdings Inc Witnesses Significant … – Best Stocks

On April 12, 2023, Creative Medical Technology Holdings Inc. (CELZ) witnessed a significant surge in their shares, which rose by over 70%. The reason behind this sudden increase was the announcement made by the company regarding the one-year follow-up data of CELZ-001. This treatment has shown significant efficacy in treating patients with spinal cord injuries. Creative Medical Technology is a renowned biotechnology company that focuses on regenerative medicine, explicitly using adult stem cell treatments to treat immunology, urology, orthopedics, and neurology. The companys patented procedure, StemSpine, treats spinal cord injuries.

The one-year follow-up data of CELZ-001 revealed that it was highly effective in treating patients with spinal cord injuries. The treatment resulted in significant improvements in motor, sensory, and bladder functions. The StemSpine procedure involves using amniotic fluid-derived stem cells for therapeutic applications. The companys core activity is stem cell research and the development of applications for treating male and female sexual dysfunction, infertility, miscarriages, and related issues.

CELZ stock has witnessed high volatility over the past year, with weekly volatility that has increased from 20% to 32%. The company has a market cap of less than $100 million and trades less than 100,000 shares daily. It is important to note that penny stocks are frequently the playground for scam artists.

On April 12, 2023, CELZ stock opened at $0.49 and had a days range of $0.44 to $0.53 with a volume of 140,113 shares traded. The average volume for the past three months was 1,832,378 shares. The market capitalization was unavailable, and the earnings growth for the past year was -112.58%. The revenue growth for the past year was +0.96%. CELZ had no P/E ratio and no price/book ratio data. The price/sales ratio was 47.02. CELZ is a health technology company in the medical specialties industry, with its corporate headquarters located in Phoenix, Arizona. CELZ is expected to report its subsequent earnings on May 31, 2023, with an EPS forecast for this quarter of -$0.10. The annual revenue for the past year was $88.6K, with a yearly profit of -$10.1M. The net profit margin was -11,449.26%.

On April 12, Creative Medical Technology Holdings Inc (CELZ) saw a significant increase in its stock performance. This was because the one analyst offering 12-month price forecasts for the company had a median target of 7.00, with a high estimate of 7.00 and a low estimate of 7.00. This represented a +1,328.57% increase from the last price of 0.49.

Link:
Creative Medical Technology Holdings Inc Witnesses Significant ... - Best Stocks

Flow Cytometry Market Size to Grow USD 104.4 Bn by 2032 … – GlobeNewswire

New York, April 11, 2023 (GLOBE NEWSWIRE) -- Market.us, a leading authority in research, reports that The global flow cytometry market size is expected to be worth around USD 104.4 Billion by 2032 from USD 51.6 Billion in 2022, growing at a CAGR of 7.5% during the forecast period from 2022 to 2032. Flow cytometry is a laser-based technology that is used to analyze the physical characteristic of cells and particles suspended in the fluid by using a laser beam. The method helps to classify cell types to decide the better treatment procedures.

Flow cytometry also detects the residual levels of disease after the treatment. Such factors help with the increasing prevalence of chronic disorders. Also, increasing the adoption of flow cytometry techniques in academics and research and initiatives in the immune-oncology and immunology field is expected to expand the growth of the flow cytometry market. However, the growing adoption of recombinant DNA technology for the production of antibodies offers significant growth opportunities in the global flow cytometry market.

Drivers and challenges have an impact on market dynamics and can impact businesses. Find some insights from a sample report@ https://market.us/report/flow-cytometry-market/request-sample/

Key Takeaway:

Factors affecting the growth of the Flow Cytometry Market?

To understand how our report can bring a difference to your business strategy, Inquire about a brochure athttps://market.us/report/flow-cytometry-market/#inquiry

Top Trends in Global Flow Cytometry Market

In drug discovery and development, the flow cytometry devices method is used for the analysis and detection of physical features of cells, which is emerged as a crucial device for exploratory and safety purposes. The emergence of these devices is due to the quick detection of a large number of cells and the creation of statistically reliable information about the partitions. With the increase in diseases, there is also the growth of clinical trials or research conducted. Clinical trials are conducted to create valuable products for people to reduce the number of infectious diseases, such factors drive the growth of the flow cytometry market.

Market Growth

The increasing adaption of flow cytometry in stem cell research and increasing application of cytometry in clinical trials it is estimated to support the growth of the flow cytometry market across the globe. The increasing incidence of HIV/AIDS, the rising use of flow cytometry technology in research, and the expansion of private and public initiatives for the growth of the flow cytometry market. The increasing rapid advancement in technology, the development of chronic diseases, and the demand for delicate and precise methods support the treatment of diseases.

Regional Analysis

On the basis of geography, the market is segmented into North America, Asia Pacific, Europe, Latin America, and Middle East, and Africa. Due to the presence of healthcare infrastructure and facilities and advanced development North America dominate the flow cytometry market in the world. Also, there is an increase in government focus and investments in technological advancement in flow cytometry devices. Such factors are responsible for the growth of the flow cytometry market in this region. Also, highly estimated research activities by pharmaceutical industries and research institutes help with the increase in demand for the growth of the market in this region. The Asia Pacific region is anticipated to show exponential growth during the projection period. The increase in the development of biotechnology and pharmaceutical companies in India and China.

Planning to lay down future strategy? Request a sample

Scope of the Report

Market Drivers:

The increase in growth of the global flow cytometry market with the growing importance of immune-oncology and immunology research growing acceptance of flow cytometry methods in clinical trials and research activities are the major driving factors for the growth of the flow cytometry market. Also, the flow cytometry meerkat gets support from growing public awareness of academic research and government investments to expand technical improvements.

The pharmaceutical sector shows a significant growth in biotechnology. The latest microfluidic research flow cytometry tools are beneficial devices for examining and handling the micron-sized particles and input of single cells. The major market players focus on their advanced development of flow cytometry devices which will drive the growth of the market during the forecast period.

Market Restraints:

The increase in the number of chronic diseases such as HIV and cancer also increased the use of flow cytometry for diagnostic purposes. But due to a lack of technological advancement and awareness among the prospective end-user, the problems, including the high cost of flow cytometry devices, are estimated to restrict the growth of the flow cytometry market.

Pharmaceutical and biotechnological industries and clinical laboratories require several flow cytometry devices to conduct many research activities, but it requires high cost for the gaining and maintenance of flow cytometry tools. Also, maintenance rates and various indirect expenses raise the total cost of these cytometry devices.

The advanced feature and facilities in the new flow cytometry devices make them more expensive. Due to the high price of flow cytometry devices, there is a decrease in demand for the adoption of flow cytometry devices. Such factors restrict the growth of the flow cytometry market.

Market Opportunities

The adaption of flow cytometry for stem cell research is significantly increasing during the forecast period. The favorable regulatory environment in developing regions and the growing use of stem cells in the treatment of many diseases drive global stem cell research activities. It is supported by the increasing number of financial support and research activities from private and public organizations.

Grow your profit margin with Market.us - Purchase Flow Cytometry Market Report athttps://market.us/purchase-report/?report_id=28460

Report Segmentation of the Flow Cytometry Market

Product Type Insight

Based on the product type, the market is segmented into instruments, software, services, and kits and reagents. The instrument segment is the most dominating segment in the flow cytometry market. Due to advanced technology and higher penetration. The advanced technology with enhanced accuracy, cost-effectiveness, and portability such factors help the growth of the market in the coming years.Due to cost-effectiveness, user-friendly, and allied advantages, the small-sized effective flow cytometers will get high acceptance in the future.

The software also witnesses for getting significant growth in this segment. The software segment is used to control generated data by the cytometers, provide the statistical analysis and analyze the information. The software is used for data analysis and acquisition during clinical diagnosis. A flow cytometer diagnoses the disease by examining the patient's samples. The BD software is specially designed for flow cytometry procedures. This software allows higher-quality experiments in significantly less time, especially for the scientist to monitor oncology, immunology, virology, and infectious diseases.

Technology Insight

Based on technology, the flow cytometry market is segmented into bead-based cytometry and cell-based cytometry. The bead-based flow cytometry is the most dominant technology during the forecast period due to procedural advancement by cell-based technology such as western blot and ElSA. Its ability to detect stability, speed, high reproducibility, and multiple analytes.

The demand for bead-based technology is increased for detecting several infectious diseases using advanced technology due to advancements in molecular engineering, coupled advantages, and cost efficiency, monoclonal antibody production. The bead-based technology is submerged with conjugated antigen molecules to measure antibodies in the fluid. It is used to measure antibody levels in biological fluids. The cell-based technology also shows lucrative growth during the forecast period.

End-User Insight

Based on end users, the market is segmented into Hospitals and Clinics, Academic and Research Institutes, Pharmaceutical, Biotechnology Companies, and Other end users. During the forecast period, the hospitals and clinics segment is the most dominant in the flow cytometry market.

Due to the increase in the prevalence of cancer, HIV, and other infectious diseases in patients, there is an increase in demand for advanced treatment and hospital visits to patients. Also, the presence of good healthcare facilities and infrastructure in hospitals and well-trained doctors in the hospitals such factors help the growth of this segment.

The rise in government policies and advanced development in flow cytometry also helps to drive this segment's growth during the forecast period. The biotechnological and pharmaceutical sectors also show a significant change in the flow cytometry market due to an increase in development activities and advanced research by the biotechnology and pharmaceutical industries. Also, expanding food industries in developing regions such as India and China also help the growth of the flow cytometry market.

To understand how our report can bring a difference to your business strategy, Ask for a brochure@ https://market.us/report/flow-cytometry-market/request-sample/

Market Segmentation

Based on Product Type

Based on Technology

By End-User

By Geography

Competitive Landscape

The competitive landscape of the market has also been examined in this report. Some of the major players include:

Recent Development of the Flow Cytometry Market

June 2022: A brand new cell organizing technology was discovered by Becton, Dickson, and Company at the International Society for the Advancement of Cytometry (ISAC) CYTO 2022. It is a new technology that enables the researcher to analyze a variety of cells at a quick speed is possible now to transform research and development of cell-based therapeutics in various fields, including oncology and virology, and other infectious diseases.

August 2021: Becton, Dickson, and the company discovered the brand-new benchtop cell analyzer known as BD FACSymphony A1 Cell Analyzer. It is expected that labs of all sizes will get benefit from the advanced flow cytometry offered by the fluorescence-activated cell analyst.

Related Reports

About Us:

Market.US(Powered by Prudour Pvt Ltd) specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicatedmarket research report-providing firm. Market.US provides customization to suit any specific or unique requirement and tailor-makes reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons.

Follow Us On LinkedIn Facebook Twitter

Our Blog:

Read the rest here:
Flow Cytometry Market Size to Grow USD 104.4 Bn by 2032 ... - GlobeNewswire

Flow Cytometry Market Size, Trend Analysis, Opportunities And … – Digital Journal

PRESS RELEASE

Published April 12, 2023

"Flow Cytometry Market Size, Growth by Technology (Cell-based, Bead-based), Product & Service (Analyzer, Sorter, Consumables, Software), Application ((Research - Immunology, Stem cell), (Clinical - Hematology)), End user (Biotech, Hospitals) - Global Forecast to 2027"

Browse 331 market data Tables and 37 Figures spread through 332 Pages and in-depth TOC on "Flow Cytometry Market - Global Forecast to 2027

Flow Cytometry Marketis projected to reachUSD 6.9 billionby 2027, at a CAGR of 8.1%according to a new report by MarketsandMarkets.The growth of the flow cytometry market is largely driven by the rising prevalence of HIV/AIDS and cancer, growing adoption of flow cytometry techniques in research activities, increasing public-private initiatives in immunology and immuno-oncology research, and rising technological advancements in flow cytometry software.

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65374584

Browse in-depth TOC on "Flow Cytometry Market"

331 - Tables

37 - Figures

332 Pages

Reagents & consumables segment held major share in flow cytometry market

Based on product & service, the flow cytometry market is segmented into reagents & consumables, instruments, software, services, and accessories. Reagents & consumables accounted for the largest share in the flow cytometry market. The large share of this segment can primarily be attributed to the growing use of flow cytometry techniques in clinical & research applications.

Research application segment dominated the global flow cytometry market

Based on applications, the flow cytometry market is segmented into research, clinical, and industrial applications. The research applications segment accounted for the largest share in the global flow cytometry market. The large share of the research applications segment is mainly due to the growing adoption of flow cytometry in research activities and the increasing availability of flow cytometry services, such as cell sorting, cell cycle analysis, and apoptosis.

North Americahas registered fastest growth rate during the forecast period in flow cytometry market

Geographically, the flow cytometry market is segmented intoNorth America,Europe, theAsia Pacific,Latin America, and theMiddle East&Africa.North Americaaccounted for the largest share in the global flow cytometry market. The large share ofNorth Americain the flow cytometry market is largely driven by the presence of key market players and increasing public-private initiatives for research activities. The market in theAsia Pacificregion is expected to grow at the highest CAGR of 8.6% during the forecast period. The high growth rate of the APAC region can be attributed to the growing pharmaceutical industry; increasing participation of emerging markets in flow cytometry-based research; expansion of research infrastructure; and increasing public-private initiatives to boost advanced proteomics research in the region.

Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=65374584

Flow Cytometry Market Dynamics:

Drivers:

Restraints:

Opportunities:

Challenges:

Key Market Players:

The prominent players in the flow cytometry market are Becton, Dickinson and Company (US), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), and Luminex Corporation (US). These companies have adopted organic and inorganic growth strategies, such as product launches and acquisitions, to maintain their leading positions in the flow cytometry market.

Recent Developments:

Get 10% Free Customization on this Report:https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=65374584

Media ContactCompany Name: MarketsandMarkets Research Private Ltd.Contact Person: Mr. Aashish MehraEmail: Send EmailPhone: 18886006441Address:630 Dundee Road Suite 430City: NorthbrookState: IL 60062Country: United StatesWebsite: https://www.marketsandmarkets.com/Market-Reports/flow-cytometry-market-65374584.html

See the original post:
Flow Cytometry Market Size, Trend Analysis, Opportunities And ... - Digital Journal

Kenneth C. Griffin makes gift to FAS – Harvard Gazette

The gift also underscores the power of graduate education, with graduate students and faculty creating new knowledge that enhances understanding across every area of study. Those students become the next generation of scholars, with some advancing knowledge and innovation as academic leaders at universities throughout the world and others applying their research to create new therapies, technologies, and tools to advance human health or help drive the economy.

Griffins gift enables such pathways and provides a firm foundation for the FAS to pursue student success and cultivate deep expertise and new collaborations across disciplines and departments.

Harvards Faculty of Arts and Sciences is committed to advancing ideas that will shape humanitys future, while providing important insight into our past, said Griffin. I am excited to support the impactful work of this great institution.

I have witnessed firsthand the impact of Kens philanthropy in my time as Dean of the Faculty of Arts and Sciences, said Claudine Gay, Edgerley Family Dean of the FAS. His extraordinary investment in our institution and, notably, his understanding of the power of unrestricted funds have been essential to our Schools ability to confidently advance academic excellence in service to the world, while navigating headwinds from the pandemic to shifts in the economy.

Griffins gift to the FAS comes at a moment of opportunity as the School undertakes a broad strategic planning process focused on delivering a forward-looking vision for excellence in graduate education, faculty support and development, and organization of academic communities. As part of that broader work in the FAS, the Graduate School convened a faculty-led working group focused on admissions and education, designed to ensure that students graduate with the potential to serve as intellectual leaders for the 21st century.

I am deeply and personally appreciative of the confidence he has placed in us and in our mission to do good in the world.

Larry Bacow, Harvard president

As the Harvard Kenneth C. Griffin Graduate School of Arts and Sciences takes on its new name, it is also marking its 150th anniversary. Situated within the FAS, Harvard Griffin GSAS offers Ph.D. and select masters degrees in over 57 departments and programs. Through degree and non-degree study and visiting and outreach programs, the School connects students with all parts of the University.

As we celebrate our sesquicentennial this year, we are looking ahead to our next 150 years and imagining what our current students will achieve, said Emma Dench, Dean of the Harvard Kenneth C. Griffin Graduate School of Arts and Sciences and McLean Professor of Ancient and Modern History and of the Classics. This investment in the Faculty of the Arts and Sciences cannot help but support our students as they engage in the inquiry and innovation that will ultimately lead to positive impact on the world.

Noting the celebration of the Schools milestone, Bacow reflected on how important graduate education and research are to Harvards mission. Graduate research helped create vaccines to curb the spread of COVID-19, a development made possible by basic research done decades ago that helped scientists understand how mRNA could be used to code proteins that incite a protective immune response, thereby controlling viral infections. Research in philosophy and ethics is now helping guide how colleges and universities educate those who are making advances in artificial intelligence. And research in data science is helping scholars and policymakers understand sources of economic opportunity and social mobility.

Griffins most recent gift builds on his previous support for faculty and students, including the $150 million gift in 2014 to expand undergraduate financial aid.

Last month, Harvard announced another expansion of the Harvard Financial Aid Initiative (HFAI) for low- and middle-income families. Beginning with the class of 2027, the cost to attend Harvard College, which includes tuition, room, board, and all fees, will be free for families with annual incomes below $85,000. This is an increase from the $75,000 annual income threshold announced last year. Today more than half of undergraduate families receive need-based scholarships and one in four families pay nothing toward the cost of a Harvard education.

Griffin, who concentrated in economics and began investing from his dorm room in Cabot House as a sophomore, has also made gifts to the Harvard Graduate School of Education, Harvard Law School, and Harvard Business School. He has supported important University priorities such as stem cell research and, recently, a professorship in economics in honor of Professor Martin Feldstein. In 1999, he established the Wayne R. Gratz Scholarship in honor of his grandfather.

Griffin is the founder and chief executive officer of Citadel, one of the worlds leading alternative investment firms. He is also the founder and non-executive chairman of Citadel Securities, one of the largest market makers in the world. His innovative philanthropic initiatives have made him a leader in advancing breakthroughs in science and medicine, enabling longer and healthier lives, as well as in expanding access and opportunity in education, equipping the next generation of leaders with the tools needed to succeed. Griffins leadership during the COVID-19 crisis helped mobilize partners across government, business, and healthcare to fund critical research and safely rescue hundreds of Americans from Wuhan, China. He also provided crucial thought leadership that laid the foundation for Operation Warp Speed a U.S. program designed to accelerate the creation and distribution of COVID-19 vaccines, therapeutics, and diagnostics.

View original post here:
Kenneth C. Griffin makes gift to FAS - Harvard Gazette

Cord Stem Cell Banking Market to Influence the Value of USD 45.64 Billion by 2030 – openPR

Cord Stem Cell Banking Market

Get Full Report: https://www.databridgemarketresearch.com/reports/global-cord-stem-cell-banking-market

Data Bridge Market Research analyses that the cord stem cell banking market, which was USD 9.3 billion in 2022, would rise up to USD 45.64 billion by 2030 and is expected to undergo a CAGR of 22% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

The cord stem cell banking market is analyzed and market size insights and trends are provided by storage type, product type, service type, source, and indication as referenced above.

The countries covered in the cord stem cell banking market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cord stem cell banking market due to an increase in the presence of major market players in the U.S., ongoing approval of stem cell lines for disease treatment, and growing awareness among the population in this region.

Asia-Pacific is expected to witness significant growth due to a rise in the elderly population, an increase in the incidence of chronic diseases, and growing per capita healthcare expenditure in this region. Also, the developing healthcare infrastructure within the region is boosting market growth.

The cord stem cell banking market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cord stem cell banking market.

Some of the major players operating in the cord stem cell banking market are:

CBR Systems, Inc., (U.S.) Cordlife (Singapore)Cryo-Cell International, Inc., (U.S.)ViaCord (U.S.)Cryo-Save (Netherlands)LifeCell International Pvt. Ltd. (India)StemCyte India Therapeutics Pvt. Ltd (U.S.)Global Cord Blood Corporation (China)Smart Cells International Limited (U.K.)Vita 34 1997 - 2023, Inc (Germany)Lisata Therapeutics, 2023 (U.S.)BrainStorm Cell Limited (U.S.)Regrow Biosciences Pvt. Ltd. (India)

Browse Other Reports:https://nipapr.blogspot.com/2023/04/hydrastatic-transmission-market-to.html

https://nipapr.blogspot.com/2023/04/label-printing-machines-market-to.html

https://nipapr.blogspot.com/2023/04/video-conferencing-mobile-voip-market.html

https://nipapr.blogspot.com/2023/04/plant-based-spreads-market-to-influence.html

https://nipapr.blogspot.com/2023/04/fine-mist-sprayers-market-to-observe.html

https://nipapr.blogspot.com/2023/04/engine-oil-packaging-market-to.html

Cord Stem Cell Banking Market to Reach USD 45.64 Billion, with an Excellent CAGR of 22% by 2030

https://www.evernote.com/shard/s393/sh/a1782e27-92ff-669e-ead0-5b7d65dbafa4/8Tix9soKMzKr1v0XvZX7ST46yAF6OE-fCcZ985ZxxMjw5BRbbE3XHJ0niQ

https://cynochat.com/read-blog/49118

https://www.gift-me.net/blogs/35424/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://diigo.com/0s9c6r

https://www.rolonet.com/blogs/174302/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://rentry.org/txpds

https://healthcareprreports.blogspot.com/2023/04/cord-stem-cell-banking-market-to-reach.html

https://www.pickmemo.com/read-blog/142927

https://www.linkedin.com/pulse/cord-stem-cell-banking-market-reach-usd-4564-billion-excellent-gupta

https://pastelink.net/0v0eqj26

https://zenwriting.net/mvmtombzdy

https://justpaste.it/d67c0

https://www.zedlike.com/blogs/74285/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://sites.google.com/view/cord-stem-cell-bankingmarket/home

https://legalledger.in/read-blog/16258

https://rollbol.com/blogs/1560937/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://demo.sngine.com/blogs/209960/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://postheaven.net/f2zlgul0wb

https://poetbook.com/read-blog/150265

https://www.shtfsocial.com/blogs/54807/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://writeablog.net/npprngli2m

https://www.campusacada.com/blogs/48578/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://kadeum.com/blogs/52069/Cord-Stem-Cell-Banking-Market-to-Reach-USD-45-64

https://cariblime.net/read-blog/48260

Contact Us:-Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:- corporatesales@databridgemarketresearch.com

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

This release was published on openPR.

See more here:
Cord Stem Cell Banking Market to Influence the Value of USD 45.64 Billion by 2030 - openPR

Scientists Enhance New Neurons to Restore Memory, Elevate Mood … – UNC Health and UNC School of Medicine

The lab of Juan Song, PhD, and colleagues at the UNC School of Medicine, demonstrated the therapeutic potential of new neurons generated in adulthood for modulating the pathology and functional deficits associated with Alzheimers disease using rodent models.

CHAPEL HILL, NC In adult human brains, the hippocampus generates new neurons (adult-born neurons, or ABNs) throughout life, helping us maintain memories and regulate emotions. Scientists call this process adult hippocampus neurogenesis (AHN). In people with Alzheimers disease (AD), this process is impaired, leading to reduced production of ABNs with poorer qualities. Given that AD patients often develop both cognitive symptoms (such as memory loss) and non-cognitive symptoms (such as anxiety and depression) for which AHN plays a critical role, one way to help Alzheimers patients achieve symptom relief could be to restore AHN.

Published in the journal Cell Stem Cell, research from UNC School of Medicine scientists demonstrated that stimulating a brain region called Supramammilary nucleus (SuM) located in the hypothalamus effectively enhanced adult-born neurons in the otherwise impaired Alzheimers brains of mice. After patterned stimulation of SuM, AD brains developed more ABNs with improved qualities. Importantly, activation of these SuM-modified ABNs restored both cognitive and affective deficits in AD mouse models.

Its been a longstanding question whether AHN can be sufficiently enhanced in impaired AD brains to improve brain function, said senior author Juan Song, PhD, associate professor of pharmacology and a Jeffrey Houpt Distinguished Investigator at the UNC School of Medicine. An important point to consider when addressing these questions is the low-level hippocampal neurogenesis, which becomes even lower in AD patients.

By manipulating a small number of ABNs in the AD brain, we demonstrate that ABNs can be enhanced even in the presence of AD pathology, and these enhanced ABNs are important for the restoration of behaviors and hippocampal function.

To enhance ABNs in AD brains, Song and colleagues adopted an elegant two-step ABN-enhancing strategy by first stimulating SuM using a patterned optogenetic paradigm with the goal of promoting the generation and developmental properties of ABNs, followed by stimulating the activity of SuM-enhanced ABNs using chemogenetics.

Optogenetics involves the use of light to alter the activity of brain cells expressing light-sensitive opsin genes. Chemogenetics involves the use of inert molecules to alter the activity of brain cells expressing designers receptors.

Interestingly, SuM stimulation alone or activation of ABNs without SuM stimulation failed to restore behavioral deficits in AD mice. Song said. These results suggest that multi-level enhancement of ABNs namely increasing their number, improving their developmental properties, and enhancing their activity is required to achieve their therapeutic benefits in AD brains.

When Song and colleagues further analyzed the protein changes in the hippocampus of AD mice in response to activation of SuM-enhanced ABNs, the researchers found that several well-known protein pathways were activated inside cells. These pathways include the ones important for synaptic plasticity of neuronal cells that allow enhanced communication among them, as well as the ones important for phagocytosis of non-neuronal microglia that allow efficient plaque clearance.

It is striking that multi-level enhancement of ABNs through combined SuM and ABN stimulations allows such a small number of ABNs make profound functional contribution in diseased AD brains, Song said. We are eager to find out the mechanisms underlying these beneficial effects mediated by activation of SuM-enhanced ABNs on AD pathology and hippocampal function. Future efforts will be needed to develop drugs that mimic these beneficial effects mediated by activation of SuM-enhanced ABNs. Ultimately, the hope is to develop first-in-class, highly targeted therapies to treat AD and related dementia.

The National Institutes of Health funded this research through grants R01MH111773, R01MH122692, RF1AG058160, R01NS104530 to Juan Song and R21AG071229, R01GM133107 to co-author Xian Chen, PhD, professor of biochemistry and biophysics at the UNC School of Medicine.

Co-first authors of the Cell Stem Cell paper are Ya-Dong Li and Yan-Jia Luo in the Song Lab. Other authors are, Ling Xie, Dalton Tart, Ryan N Sheehy, Libo Zhang, and Leon G Coleman Jr, all at the UNC School of Medicine.

Media contact: Mark Derewicz, 919-923-0959

See more here:
Scientists Enhance New Neurons to Restore Memory, Elevate Mood ... - UNC Health and UNC School of Medicine

Proliferation, not replication: HIV is lifelong because infected cells … – aidsmap

A poster and a talk both presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2023) dampened down expectations that a cure for HIV may soon be possible using less risky and expensive methods than the stem-cell transplants that have so far cured five people (see this report for the latest).

Dr Natalie McMyn of Johns Hopkins University has found that, although during the first few years on antiretroviral therapy (ART) the number of cells capable of producing viable HIV (if ART is stopped) shrinks, in people taking ART continuously for a longer time, the size of this reservoir of virally-productive cells declines no more and may even slowly start to increase. The amount of cells withanyHIV DNA in them, whether productive or not, also stops declining after ten or so years on ART and may increase.

McMyns study is co-authored by several leaders in HIV cure research, including Professors Steven Deeks, Robert Siliciano and Janet Siciliano.

The HIV reservoir is a group of cells that are infected with HIV but have not produced new HIV (latent stage of infection) for many months or years. Latent HIV reservoirs are established during the earliest stage of HIV infection. Although antiretroviral therapycan reduce the level of HIV in the blood to an undetectable level, latent reservoirs of HIV continue to survive (a phenomenon called residual inflammation). Latently infected cells may be reawakened to begin actively reproducing HIV virions if antiretroviral therapy is stopped.

To eliminate a disease or a condition in an individual, or to fully restore health. A cure for HIV infection is one of the ultimate long-term goals of research today. It refers to a strategy or strategies that would eliminate HIV from a persons body, or permanently control the virus and render it unable to cause disease. A sterilising cure would completely eliminate the virus. A functional cure would suppress HIV viral load, keeping it below the level of detection without the use of ART. The virus would not be eliminated from the body but would be effectively controlled and prevented from causing any illness.

The chemical form in which HIV's genetic information is stored within infected cells.

The body's mechanisms for fighting infections and eradicating dysfunctional cells.

Its implications were explored ina talk given by Dr Jared Sternof Seattles Fred Hutch Cancer Institute at theCommunity Cure Workshop held the day before CROI opened.

Stern said that strategies aiming to cure HIV either by targeting cells for immune destruction (the shock and kill strategy) or by forcing them into permanent quiescence (the block and lock strategy) may not be sufficient in themselves to achieve a cure for HIV. A delicate, sequential balance of different strategies may be necessary.

The reason for the eventual stabilisation and even growth of the reservoir is that in the early years on ART, many cells remain that are capable of actively producing HIV viral particles. This is why the average viral load in people on ART is, at least initially, in the region of 2-4 copies per millilitre instead of zero.

When these cells do produce viable HIV, while they can infect new cells, they also become visible to the immune system. This both targets them for immune destruction, and sets them on the pathway towards apoptosis programmed cell death.

Later on however, cell division, rather than viral replication, becomes more important.Even the long-lived T-memory cells that form most of the viral reservoir have to divide now and then in order to replenish the bodys T-cells, often in response to infection. Because of this, later on, active viral production becomes rarer and the reservoir is mainly replenished by cell division.

When infected cells divide, they do not have to express HIV proteins or otherwise start the process of making virus they simply split, duplicating their DNA, including their HIV proviral DNA, as they do. These cells contain identical clones of HIV, because DNA has much less chance to mutate during cell division. This is called clonal expansion.

McMyns study involved 31 people who had been on fully-suppressive ART for a median time of nearly 23 years. All have maintained viral undetectability. Starting with CD4 counts of near-zero (this was the late 1990s), their median CD4 count rose to about 800 15 years after starting ART, but after that declined a little and plateaued at around 650.

The researchers took purified resting CD4 T-cells from each participants blood and did two tests. Firstly, they did a viral outgrowth assay. This measures the proportion of cells that can be induced to produce viral particles in the lab dish.

Previous investigations by Robert Siliciano in the early 2000s found a slow decrease in productive cells. He calculated that the HIV reservoir had a half-life of 44 months on ART, meaning the number of virally productive cells would halve in just over two years. This would mean that two per million resting CD4 cells being able to produce viable virus at baseline, that number would have gone down tenfold in 12 years and a hundredfold in 24.

This was not what they observed: the proportion of cells that were productively infected went down for the first 3-4 years on ART but then stopped decreasing and may even have increased very slightly since then.

The other test was a DNA assay of the cells, to detectallcells that contained lengths of proviral DNA. Because most of these are fragmentary or mutated and so cant produce virus, about 100 times as many CD4 T-cells contain proviral DNA than can produce viable virus. If the trend indicated by earlier studies continued, wed expect the proportion of cells containing HIV DNA to decline from 200 per million to two per million in 24 years too.

But the proviral DNA reservoir only declined in about the first nine years on ART and even then by not very much. After that it stayed steady or grew slightly and is now back to where it started in most of the participants studied. The proportion of DNA-containing cells that could produce viable virus was the same regardless of the amount of time on ART. The amount of DNA-containing cells and productively-infected cells differed by two orders of magnitude between the 31 individuals, but were correlated within individuals.

By successively diluting cell samples, the researchers genetically sequenced every DNA sequence in the CD4 resting T-cells they sampled in three individuals. From two of these people, viable virus could be produced from some samples, but not from the third persons cells. In this individual, virtually all viral isolates (DNA sequences) were genetically distinct from each other. Only three out of 44 sequences formed a pair with one of the other ones, indicating cloned DNA.

In the other two people, 19% of 59, and 36% of 97 proviral DNA sequences gave rise to fully replicating virus. In the first case, every single sequence that produced viable virus was identical, clearly originating from one single cell that had divided. There were three other clonal sequences that did not produce virus.

In the second case, 18 out of the 35 sequences that produced virus were identical, and three others almost identical. The other 14 productive sequences were, however, all different from each other apart from one pair, and there were 11 other clonal sequences that did not produce virus. These were mainly pairs and triads of identical sequences, but there was one clone of seven cells with identical DNA that was not productive.

Natalie McMyns main conclusion from her findings was that, while in some cases the HIV reservoir may stop being capable of producing new virus, in the large majority, cellular proliferation keeps the reservoir of cells containing viable virus topped up so we should not expect there to be too many people who can stop ART without their viral load bouncing back.

Jared Stern drew wider conclusions from this and related studies.

He said that as time goes by, the reservoir changes its nature under ART. Because active cells are cleared or self-destruct more quickly than inactive ones, over time the reservoir becomes less productive and more latent.

ART is good at preventing cells from becoming infected, he said. But its no good at stopping them staying infectious.

More latent means less likely to activate, but also less visible to the immune system which creates a dilemma for cure researchers. Should they attempt to activate more cells and alert the immune system, risking the danger of enlarging the reservoir with a new wave of cellular infections or should they try to maintain latency, even though in some people that means maintaining cells that will contain persistently viable viral DNA?

Essentially, people with HIV face a lottery during acute HIV infection. The virus' position of integration into a cells nucleus is rather random but it tends to pick sites nearest to the exterior of the nucleus, and these tend to be the areas where commonly active genes are being expressed. If HIV finds itself in a length of DNA that is rarely or never expressed the so-called gene deserts then even if the cell divides, it is unlikely ever to start producing virus.

On the other hand, if it is integrated into a gene that is often active, then it will likely be expressed when the gene activates. ART stops HIVs enzymes from getting very far into the process of producing viral components but it does not stop the cell dividing and cloning those potentially productive sequences.

This implies that before we can devise a safer and cheaper cure for HIV than wholesale replacement of the immune system, we need to answer some outstanding research questions we dont know the answer to.

What determines whether a cell becomes productive (and so dies) or latent (and therefore survives)? What determines that a cell switches from being latent to being productive? Why do some T-memory cells divide clonally and not others? Does HIV itself have a part to play in clonal expansion?

Should a cure make HIV less, or more, latent? Is long-term ART sufficient, at least in some proportion of people, to produce a deeply latent reservoir that cant rebound when ART is stopped? And how do we know who those people are?

Go here to read the rest:
Proliferation, not replication: HIV is lifelong because infected cells ... - aidsmap

Trudy Oliver Tracks a Deadly, Shapeshifting Tumor – Duke University School of Medicine

Trudy Oliver, PhD, studies a type of cancer that has a 5-year overall survival rate of just 7%. Its biological drivers are different from most other cancers, so its harder to develop targeted treatments. On top of that, research into this tumor is under-funded.

Oliver, professor of pharmacology and cancer biology at Duke University School of Medicine, investigates small cell lung cancer, which is almost always linked to cigarette smoking. "Some people think 'Oh, you smoked. You got what you deserved. Why do we need to put money into this? she said.

Whatever you think about that statement, Olivers work suggests that it doesnt matter. Small cell lung cancer is a shapeshifter. Her recent research found that it evolves nimbly, changing identities in order to survive. Increasingly, scientists are finding that many cancers have this "plasticity" to some extent, especially when they are threatened by ever-more targeted treatments.

Because of that, small cell lung cancer has much more in common with other cancers than previously thought. "In order to understand how to treat any kind of cancer, we have to study them all," Oliver said.

Oliver joined the Duke faculty in July 2021 as a Duke Science and Technology Scholar. She earned a PhD at Duke in 2005, and after a faculty position at the Huntsman Cancer Institute at the University of Utah, she returned to Duke for the chance to forge new collaborations. "I really wanted to be exposed to new science and new ways of thinking," she said.

Oliver has made progress with small cell lung cancer by systematically profiling it. For the past 30 years, all patients with the disease have been treated the same, with chemotherapy. In the last handful of years, Oliver and other researchers have shown that they can divide the disease into at least four different subtypes, each of which responds differently to treatment. Some of this work has been translated into human clinical trials. For instance, in 2017 her lab showed that one subtype responds best to a class of drugs known as aurora kinase inhibitors, and in a clinical trial published in 2020, other researchers showed that a specific aurora kinase inhibitor worked better in patients with this subtype.

But the difference was small. "The sad part is that even though the aurora kinase inhibitor works better at extending survival in this subset of patients, the amount of benefit they get is only about two or three months," Oliver said. "That's the scale of things people see in small cell, because it's so deadly and aggressive. I believe we can do better than that."

The key to doing better, Oliver believes, is harnessing this cancer's ability to shapeshift. In a 2020 study published in CancerCell, Oliver and PhD student Abbie Ireland and colleagues reported that small cell lung cancer can cycle through different identities with ease, and that multiple subtypes are present within a single tumor.

This process is not easy to manipulate because its driven by proteins called transcription factors, which don't have a defined structure where drugs could bind. Transcription factors turn programs of genes on or off, determining a cell's reason for being, Oliver said. "Transcription factors are responsible for creating a cell's identity and its job. A transcription factor makes you a policeman versus a firefighter versus a teacher."

Oliver works to predict and then control what form the cancer will take at any given time by looking for clues in stem cell biology and early lung development. "We see that the different identities that small cell lung cancer takes on are mimicking the same identities that it had access to during embryonic development," she said. As one cell multiplies into two, then a mass of cells, then a pair of lungs, these cells take on different forms. Cancer seems to remember and make use of those identities to survive, especially in the face of good treatments.

"Certain cancer cell fates have particular needs and demands, and if you really shut down who they are, they just convert to something else," Oliver said.

This shapeshifting also happens in other cancers, including lung adenocarcinoma, which is the most common type of lung cancer that is diagnosed in people who have never smoked. "We have really good treatments for lung adenocarcinoma, and the patients have these dramatic responses. But then their tumor converts to a different fate because you've shut down the key pathway," Oliver said. "They convert to neuroendocrine tumors, which are basically smoking-associated tumors."

Oliver gravitates to the hardest problems. After her PhD at Duke and then a postdoctoral fellowship at MIT where she worked with Tyler Jacks, PhD, "the best mouse model person in the world," she started her own lab at Huntsman Cancer Institute in Utah in 2011, focusing on the neglected forms of lung cancer. "We had made a bunch of sophisticated models for lung adenocarcinoma, and lots of people were working on it," Oliver said. "But for the other lung cancer types we didn't have great models, so we couldn't ask the important questions."

Just a couple of months after Oliver arrived at Duke, she found one of those new collaborations she had been looking for, studying another neglected tumor type. Her first year at Duke was designated as protected time for moving her lab, but she agreed to help teach a grant-writing course because she saw it as a good way to meet students and learn about their research.

When Oliver read the title of the National Institutes of Health predoctoral fellowship grant application that MD-PhD candidate Jack Finlay was working on, she immediately wrote an email to him and his mentor, Bradley Goldstein, MD, PhD, associate professor of head and neck surgery and communication sciences. Finlay was using computational biology to study a rare nasal tumor called olfactory neuroblastoma. And Oliver knew of Goldstein's reputation as a leader in studying tissue and diseases inside the nose. "That really caught my attention because I knew from years ago that some of our mouse models we were using for small cell lung cancer were getting these olfactory tumors," Oliver said. "I really wanted to know what these tumors were, but I didn't know an expert in Utah in that field."

Finlay said the collaboration has given him a more nuanced understanding of the biology of the cancer that he plans to treat and study as an otolaryngologist and head and neck surgeon. "The first question we had was, are these really olfactory neuroblastomas in Dr. Oliver's mice? And we've since confirmed that they are," Finlay said. "So we think we have the first mouse model of this tumor, which is huge."

Designing a model like this from scratch would involve engineering the mouse tumors to express the same genetic mutations that are seen in human tumors, he said. Since olfactory neuroblastoma is rare and understudied, many of those details aren't known. "It's hard to even envision how you would begin to make a mouse model," he said.

Finlay is excited about the possibility of using the mice to test potential non-surgical treatments for olfactory neuroblastoma. The standard of care for these tumors is surgery, which is often extensive and disfiguring for the patient because the tumors are so aggressive. "We really don't have many options besides just taking out as much of the tissue as possible," Finlay said.

Finlay visits the Oliver lab at least once a week. "It's a fun, lively environment, whether they're having scientific discussions or troubleshooting a cell line," he said. In addition, he and Goldstein meet with Oliver, PhD student Abbie Ireland, and research technician Bryony Hawgood every couple of months for data review and presentations. "That will go on for hours," Finlay said. Pizza is usually on the table.

Early studies of the mice suggest that these olfactory tumors use some of the same means of survival as small cell lung cancer and treatment-resistant prostate cancer, Oliver said. "We hope we're going to bring together people from the prostate cancer field and the lung field and the olfactory field to appreciate that we're all studying a very similar disease."

Angela Spivey is a senior science writer and managing editor for the School of Medicines Office of Strategic Communications.

Photos by Alex Boerner. Video by Jim Rogalski.

Main image: Trudy Oliver, PhD, professor of pharmacology and cancer biology at Duke University School of Medicine and a Duke Science and Technology Scholar.

Read the original:
Trudy Oliver Tracks a Deadly, Shapeshifting Tumor - Duke University School of Medicine

Fox Chase Cancer Center is Holding a ‘Be The Match’ Virtual Event – Fox Chase Cancer Center

April is National Donate Life Month, and Fox Chase Cancer Center and Temple Health are hosting a Be The Match virtual event.

PHILADELPHIA (April 6, 2023) April is National Donate Life Month, and Fox Chase Cancer Center and Temple Health are kicking off the month with a Be The Match virtual event.

Be The Match is a nonprofit organization and global leader in blood stem cell transplantsometimes called bone marrow transplantfocusing on improving outcomes, support, and resources for patients with cancers and blood diseases like sickle cell anemia. Cancers that typically affect bone marrow function include leukemias, multiple myeloma, and lymphomas, all of which originate in the blood cells. For certain types of these cancers, transplants can be an important part of treatment.

During stem cell transplantation, a patient whose stem cells have been destroyed by cancer or its treatment will receive healthy blood-forming stem cells from a donor to replace their own. These stem cells are predominately taken from blood; a small portion are taken from bone marrow. Only 30% of patients have a matching donor in their families, so the remaining 70% must search the Be The Match Registry to find a matching donor.

Fox Chases Department of Bone Marrow Transplant (BMT) and Cellular Therapies is one of the leading programs in the country. Its outpatient and inpatient units occupy the entire fifth floor of the Patient Care Center at Temple University Hospital Jeanes Campus.

To sign up for the registry, individuals between the ages of 18 and 40 can text BMT to 61474 and complete a brief health history. Be The Match will send you a cheek swab kit in the mail within a few days. From there, simply complete your swab test and return it to Be The Match using the prepaid envelope.

Using the swab kit that you send in, Be The Match determines your human leukocyte antigen (HLA) typea protein found in most cells of the bodyto compare with HLA markers of patients who need a bone marrow transplant.

It may take months or even years to find a match, and being on the registry doesnt guarantee you will ever be matched to a patient in need. A donor and recipient do not need to have the same blood type, but patients are more likely to match with donors with similar ethnic backgrounds. If you are identified as a match for a patient, Be The Match will move quickly to take the next steps in coordinating a donation as you may be the only option for a patient seeking a life-saving stem cell transplant.

There are two ways to donate blood stem cells or marrow. The first process, which is used 90% of the time, is a nonsurgical peripheral blood stem cell collection that resembles plasma donation. The second process is marrow extraction, a surgical procedure performed under anesthesia.

Many donors say they experience little to no pain during the process of donating. There can be some discomfort during recovery that varies from person to person. Side effects can include back pain, fatigue, headache, and bruising for a few days or weeks, but many donors say they would do it again to save a life.

For further information, contact Rebecca Farrell, Clinical Manager at Fox Chase, at 215-214-3738.

View original post here:
Fox Chase Cancer Center is Holding a 'Be The Match' Virtual Event - Fox Chase Cancer Center